keyword
MENU ▼
Read by QxMD icon Read
search

Arcaini

keyword
https://www.readbyqxmd.com/read/27784957/antiviral-therapy-of-hepatitis-c-as-curative-treatment-of-indolent-b-cell-lymphoma
#1
REVIEW
Michele Merli, Giuseppe Carli, Luca Arcaini, Carlo Visco
The association of hepatitis C virus (HCV) and B-cell non-Hodgkin lymphomas (NHL) has been highlighted by several epidemiological and biological insights; however the most convincing evidence is represented by interventional studies demonstrating the capability of antiviral treatment (AT) with interferon (IFN) with or without ribavirin to induce the regression of indolent lymphomas, especially of marginal-zone origin. In the largest published retrospective study (100 patients) the overall response rate (ORR) after first-line IFN-based AT was 77% (44% complete responses) and responses were sustainable (median duration of response 33 mo)...
October 14, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27665744/primary-cutaneous-b-cell-lymphoma-other-than-marginal-zone-clinicopathologic-analysis-of-161-cases-comparison-with-current-classification-and-definition-of-prognostic-markers
#2
Marco Lucioni, Emilio Berti, Luca Arcaini, Giorgio A Croci, Aldo Maffi, Catherine Klersy, Gaia Goteri, Carlo Tomasini, Pietro Quaglino, Roberta Riboni, Mariarosa Arra, Elena Dallera, Vieri Grandi, Mauro Alaibac, Antonio Ramponi, Sara Rattotti, Maria Giuseppina Cabras, Silvia Franceschetti, Giulio Fraternali-Orcioni, Nicola Zerbinati, Francesco Onida, Stefano Ascani, Maria Teresa Fierro, Serena Rupoli, Marcello Gambacorta, Pier Luigi Zinzani, Nicola Pimpinelli, Marco Santucci, Marco Paulli
Categorization of primary cutaneous B-cell lymphomas (PCBCL) other than marginal zone (MZL) represents a diagnostic challenge with relevant prognostic implications. The 2008 WHO lymphoma classification recognizes only primary cutaneous follicular center cell lymphoma (PCFCCL) and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT), whereas the previous 2005 WHO/EORTC classification also included an intermediate form, namely PCDLBCL, other. We conducted a retrospective, multicentric, consensus-based revision of the clinicopathologic characteristics of 161 cases of PCBCL other than MZL...
September 26, 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27640316/international-diagnostic-guidelines-for-patients-with-hcv-related-extrahepatic-manifestations-a-multidisciplinary-expert-statement
#3
Clodoveo Ferri, Manuel Ramos-Casals, Anna Linda Zignego, Luca Arcaini, Dario Roccatello, Alessandro Antonelli, David Saadoun, Anne Claire Desbois, Marco Sebastiani, Milvia Casato, Peter Lamprecht, Alessandra Mangia, Athanasios G Tzioufas, Zobair M Younossi, Patrice Cacoub
Hepatitis C virus (HCV) infection is responsible for both hepatic and extra-hepatic disorders (HCV-EHDs); these latter are correlated on one hand clearly with HCV lymphotropism causing immune-system dysregulation as well as with viral oncogenic potential, and on the other hand probably with chronic inflammatory status causing cardio-metabolic complications as well as neurocognitive disturbances. The spectrum of HCV-EHDs ranges from mild or moderate manifestations, such as arthralgia, sicca syndrome, peripheral neuropathy, to severe, life-threatening complications, mainly vasculitis and neoplastic complications...
September 16, 2016: Autoimmunity Reviews
https://www.readbyqxmd.com/read/27605512/interferon-free-antiviral-treatment-in-b-cell-lymphoproliferative-disorders-associated-with-hepatitis-c-virus-infection
#4
Luca Arcaini, Caroline Besson, Marco Frigeni, Helene Fontaine, Maria Goldaniga, Milvia Casato, Marcella Visentini, Harrys A Torres, Veronique Loustaud-Ratti, Jan Peveling-Oberhag, Paolo Fabris, Roberto Rossotti, Francesco Zaja, Luigi Rigacci, Sara Rattotti, Raffaele Bruno, Michele Merli, Céline Dorival, Laurent Alric, Arnaud Jaccard, Stanislas Pol, Fabrice Carrat, Virginia Valeria Ferretti, Carlo Visco, Olivier Hermine
Regression of hepatitis C virus (HCV)-associated lymphoma with interferon-based antiviral treatment supports an etiological link between lymphoma and HCV infection. In addition, a favorable impact of antiviral treatment on overall survival of patients with HCV-related lymphoma has been reported. Data on IFN-free regimens combining direct-acting antivirals (DAAs) in HCV-associated lymphoproliferative disorders are scanty. We analyzed virological and lymphoproliferative disease response (LDR) of 46 patients with indolent B-cell non-Hodgkin lymphomas (NHL) or chronic lymphocytic leukemia (CLL) and chronic HCV infection treated with DAAs...
September 7, 2016: Blood
https://www.readbyqxmd.com/read/27416486/new-uses-for-brentuximab-vedotin-and-novel-antibody-drug-conjugates-in-lymphoma
#5
Michele Merli, Andrea Ferrario, Margherita Maffioli, Cecilia Olivares, Alessandra Stasia, Luca Arcaini, Francesco Passamonti
INTRODUCTION: Brentuximab vedotin (BV) is a potent anti-CD30 antibody drug conjugate (ADC) that has been approved in relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT) and anaplastic large-cell lymphoma (ALCL). Beyond these consolidated indications, BV has been tested in a number of different settings with promising results, leading for example to the recent approval as a consolidation after ASCT in high-risk HL patients. AREAS COVERED: Main emerging areas of clinical investigation of BV include the use as a single-agent or in combination with bendamustine in first-salvage therapy of HL (bridge to ASCT), in the frontline setting in combination with AVD chemotherapy in HL and with CHP in ALCL, in relapsed or refractory cutaneous T-cell lymphomas and finally in diffuse large B-cell lymphomas (DLBCL) expressing CD30...
August 2016: Expert Review of Hematology
https://www.readbyqxmd.com/read/27335277/the-genetics-of-nodal-marginal-zone-lymphoma
#6
Valeria Spina, Hossein Khiabanian, Monica Messina, Sara Monti, Luciano Cascione, Alessio Bruscaggin, Elisa Spaccarotella, Antony B Holmes, Luca Arcaini, Marco Lucioni, Fabrizio Tabbò, Sakellarios Zairis, Fary Diop, Michaela Cerri, Sabina Chiaretti, Roberto Marasca, Maurilio Ponzoni, Silvia Deaglio, Antonio Ramponi, Enrico Tiacci, Laura Pasqualucci, Marco Paulli, Brunangelo Falini, Giorgio Inghirami, Francesco Bertoni, Robin Foà, Raul Rabadan, Gianluca Gaidano, Davide Rossi
Nodal marginal zone lymphoma (NMZL) is a rare, indolent B-cell tumor that is distinguished from splenic marginal zone lymphoma (SMZL) by the different pattern of dissemination. NMZL still lacks distinct markers and remains orphan of specific cancer gene lesions. By combining whole-exome sequencing, targeted sequencing of tumor-related genes, whole-transcriptome sequencing, and high-resolution single nucleotide polymorphism array analysis, we aimed at disclosing the pathways that are molecularly deregulated in NMZL and we compare the molecular profile of NMZL with that of SMZL...
September 8, 2016: Blood
https://www.readbyqxmd.com/read/27060262/independent-prognostic-impact-of-tumour-infiltrating-macrophages-in-early-stage-hodgkin-s-lymphoma
#7
Manuel Gotti, Marta Nicola, Marco Lucioni, Valeria Fiaccadori, Virginia Ferretti, Roberta Sciarra, Mariangela Costanza, Elisa Bono, Silvana Molo, Aldo Maffi, Giorgio A Croci, Marzia Varettoni, Marco Frigeni, Cristiana Pascutto, Luca Arcaini, Maurizio Bonfichi, Marco Paulli, Mario Cazzola
Although patients with early-stage Hodgkin's lymphoma have a high rate of cure, a portion of these are resistant to or relapse after standard treatment. Current prognostic criteria based on clinical and laboratory parameters at diagnosis do not allow to accurately identify the subset of patients with less favourable clinical outcome. An increased number of tumour-infiltrating macrophages was found to be associated with shortened survival in patients with classic Hodgkin's Lymphoma. The aim of this study was to assess the clinical significance of the proportion of CD68-positive infiltrating macrophages in patients with early-stage classic Hodgkin's lymphoma...
April 6, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27054025/hepatitis-c-virus-associated-b-cell-non-hodgkin-s-lymphomas-what-do-we-know
#8
REVIEW
Barbara Vannata, Luca Arcaini, Emanuele Zucca
Epidemiological studies have shown an increased risk of developing B-cell lymphomas in patients with chronic hepatitis C virus (HCV) infection. There is, however, a great geographic variability and it remains unclear whether additional environmental and genetic factors are involved or whether the international discrepancies represent simply a consequence of the variable prevalence of HCV infection in different countries. Other confounding factors may affect the comparability of the different studies, including the method of HCV assessment, the selection of normal controls, the lymphoma classification used and the year of publication...
April 2016: Therapeutic Advances in Hematology
https://www.readbyqxmd.com/read/26989207/splenic-marginal-zone-lymphoma-from-genetics-to-management
#9
REVIEW
Luca Arcaini, Davide Rossi, Marco Paulli
Splenic marginal zone lymphoma (SMZL) is a rare B-cell malignancy involving the spleen, bone marrow, and frequently the blood. SMZL lymphomagenesis involves antigen and/or superantigen stimulation and molecular deregulation of genes (NOTCH2 and KLF2) involved in the physiological differentiation of spleen marginal zone B cells. Diagnosis requires either spleen histology or, alternatively, the documentation of a typical cell morphology and immunophenotype on blood cells coupled with the detection of intrasinusoidal infiltration by CD20(+) cells in the bone marrow...
April 28, 2016: Blood
https://www.readbyqxmd.com/read/26924533/the-anti-lymphoma-activity-of-antiviral-therapy-in-hcv-associated-b-cell-non-hodgkin-lymphomas-a-meta-analysis
#10
J Peveling-Oberhag, L Arcaini, K Bankov, S Zeuzem, E Herrmann
Many epidemiological studies provide solid evidence for an association of chronic hepatitis C virus (HCV) infection with B-cell non-Hodgkin's lymphoma (B-NHL). However, the most convincing evidence for a causal relationship between HCV infection and lymphoma development is the observation of B-NHL regression after HCV eradication by antiviral therapy (AVT). We conducted a literature search to identify studies that included patients with HCV-associated B-NHL (HCV-NHL) who received AVT, with the intention to treat lymphoma and viral disease at the same time...
July 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/26899778/lenalidomide-versus-investigator-s-choice-in-relapsed-or-refractory-mantle-cell-lymphoma-mcl-002-sprint-a-phase-2-randomised-multicentre-trial
#11
RANDOMIZED CONTROLLED TRIAL
Marek Trněný, Thierry Lamy, Jan Walewski, David Belada, Jiri Mayer, John Radford, Wojciech Jurczak, Franck Morschhauser, Julia Alexeeva, Simon Rule, Boris Afanasyev, Kamil Kaplanov, Antoine Thyss, Alexej Kuzmin, Sergey Voloshin, Kazimierz Kuliczkowski, Agnieszka Giza, Noel Milpied, Caterina Stelitano, Reinhard Marks, Lorenz Trümper, Tsvetan Biyukov, Meera Patturajan, Marie-Laure Casadebaig Bravo, Luca Arcaini
BACKGROUND: Lenalidomide, an immunomodulatory drug with antineoplastic and antiproliferative effects, showed activity in many single-group studies in relapsed or refractory mantle cell lymphoma. The aim of this randomised study was to examine the efficacy and safety of lenalidomide versus best investigator's choice of single-agent therapy in relapsed or refractory mantle cell lymphoma. METHODS: The MCL-002 (SPRINT) study was a randomised, phase 2 study of patients with mantle cell lymphoma aged 18 years or older at 67 clinics and academic centres in 12 countries who relapsed one to three times, had Eastern Cooperative Oncology Group performance status of 0-2, at least one measurable lesion to be eligible, and who were ineligible for intensive chemotherpy or stem-cell transplantation...
March 2016: Lancet Oncology
https://www.readbyqxmd.com/read/26687955/dulanermin-in-indolent-lymphomas-an-ineffective-approach
#12
COMMENT
Luca Arcaini
No abstract text is available yet for this article.
April 2015: Lancet Haematology
https://www.readbyqxmd.com/read/26659815/clonal-architecture-of-cxcr4-whim-like-mutations-in-waldenstr%C3%A3-m-macroglobulinaemia
#13
Lian Xu, Zachary R Hunter, Nicholas Tsakmaklis, Yang Cao, Guang Yang, Jie Chen, Xia Liu, Sandra Kanan, Jorge J Castillo, Yu-Tzu Tai, James L Zehnder, Jennifer R Brown, Ruben D Carrasco, Ranjana Advani, Jean M Sabile, Kimon Argyropoulos, M Lia Palomba, Enrica Morra, Alessandra Trojani, Antonino Greco, Alessandra Tedeschi, Marzia Varettoni, Luca Arcaini, Nikhil M Munshi, Kenneth C Anderson, Steven P Treon
CXCR4(WHIM) somatic mutations are distinctive to Waldenström Macroglobulinaemia (WM), and impact disease presentation and treatment outcome. The clonal architecture of CXCR4(WHIM) mutations remains to be delineated. We developed highly sensitive allele-specific polymerase chain reaction (AS-PCR) assays for detecting the most common CXCR4(WHIM) mutations (CXCR4(S338X C>A and C>G) ) in WM. The AS-PCR assays detected CXCR4(S338X) mutations in WM and IgM monoclonal gammopathy of unknown significance (MGUS) patients not revealed by Sanger sequencing...
March 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/26379040/a-phase-ii-study-of-bendamustine-in-combination-with-rituximab-as-initial-treatment-for-patients-with-indolent-non-follicular-non-hodgkin-lymphoma
#14
Stefano Luminari, Maria Goldaniga, Marina Cesaretti, Lorella Orsucci, Alessandra Tucci, Alessandro Pulsoni, Flavia Salvi, Luca Arcaini, Angelo Michele Carella, Alessandra Tedeschi, Antonello Pinto, Caterina Stelitano, Luca Baldini
The purpose of this phase 2 study was to determine the activity and safety of six cycles of bendamustine and eight rituximab (RB) as first-line treatment of adult patients with advanced stage non-follicular indolent non-Hodgkin lymphomas (INFL). The primary end-point was the complete response rate (CRR) with expected CRR of 75%. Sixty-nine patients were enrolled; median age was 65 years (45-75), 65% were male, 93% of patients had stage IV disease. Complete and overall response rates were 48% (95% CI = 35...
2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/25675120/everolimus-in-diffuse-large-b-cell-lymphomas
#15
REVIEW
Michele Merli, Andrea Ferrario, Margherita Maffioli, Luca Arcaini, Francesco Passamonti
Satisfactory treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is not currently available and novel therapies are needed. mTOR is an intracellular kinase that is part of an aberrantly activated pathway in DLBCL. Preclinical studies in DLBCL cell lines demonstrated that everolimus, an oral selective mTOR inhibitor, induces cell cycle arrest and is synergistic with rituximab. Phase I studies indicated 10 mg daily to be the best dosing of everolimus in DLBCL. A large Phase II study in relapsed/refractory DLBCL confirmed the substantial activity (overall response rate: 30%) and good tolerability of everolimus in DLBCL, with thrombocytopenia being the main toxicity...
2015: Future Oncology
https://www.readbyqxmd.com/read/25612624/dna-methylation-profiling-identifies-two-splenic-marginal-zone-lymphoma-subgroups-with-different-clinical-and-genetic-features
#16
MULTICENTER STUDY
Alberto J Arribas, Andrea Rinaldi, Afua A Mensah, Ivo Kwee, Luciano Cascione, Eloy F Robles, Jose A Martinez-Climent, David Oscier, Luca Arcaini, Luca Baldini, Roberto Marasca, Catherine Thieblemont, Josette Briere, Francesco Forconi, Alberto Zamò, Massimiliano Bonifacio, Manuela Mollejo, Fabio Facchetti, Stephan Dirnhofer, Maurilio Ponzoni, Govind Bhagat, Miguel A Piris, Gianluca Gaidano, Emanuele Zucca, Davide Rossi, Francesco Bertoni
Splenic marginal zone lymphoma is a rare lymphoma. Loss of 7q31 and somatic mutations affecting the NOTCH2 and KLF2 genes are the commonest genomic aberrations. Epigenetic changes can be pharmacologically reverted; therefore, identification of groups of patients with specific epigenomic alterations might have therapeutic relevance. Here we integrated genome-wide DNA-promoter methylation profiling with gene expression profiling, and clinical and biological variables. An unsupervised clustering analysis of a test series of 98 samples identified 2 clusters with different degrees of promoter methylation...
March 19, 2015: Blood
https://www.readbyqxmd.com/read/25596266/the-genotype-of-mlh1-identifies-a-subgroup-of-follicular-lymphoma-patients-who-do-not-benefit-from-doxorubicin-fil-foll-study
#17
RANDOMIZED CONTROLLED TRIAL
Davide Rossi, Alessio Bruscaggin, Piera La Cava, Sara Galimberti, Elena Ciabatti, Stefano Luminari, Luigi Rigacci, Alessandra Tucci, Alessandro Pulsoni, Giovanni Bertoldero, Daniele Vallisa, Chiara Rusconi, Michele Spina, Luca Arcaini, Francesco Angrilli, Caterina Stelitano, Francesco Merli, Gianluca Gaidano, Massimo Federico, Giuseppe A Palumbo
Though most follicular lymphoma biomarkers rely on tumor features, the host genetic background may also be relevant for outcome. Here we aimed at verifying the contribution of candidate polymorphisms of FCγ receptor, DNA repair and detoxification genes to prognostic stratification of follicular lymphoma treated with immunochemotherapy. The study was based on 428 patients enrolled in the FOLL05 prospective trial that compared three standard-of-care regimens (rituximab-cyclophosphamide-vincristine-prednisone versus rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone versus rituximab-fludarabine-mitoxantrone) for the first line therapy of advanced follicular lymphoma...
April 2015: Haematologica
https://www.readbyqxmd.com/read/25502635/autologous-stem-cell-transplantation-with-in-vivo-purged-progenitor-cells-shows-long-term-efficacy-in-relapsed-refractory-follicular-lymphoma
#18
MULTICENTER STUDY
Luca Arcaini, Lucia Morello, Alessandra Tucci, Chiara Rusconi, Marco Ladetto, Sara Rattotti, Maurizio Bonfichi, Chiara Bottelli, Cristina Gabutti, Paolo Bernasconi, Marzia Varettoni, Manuel Gotti, Daniela Troletti, Maria Luisa Guerrera, Valeria Fiaccadori, Roberta Sciarra, Virginia Valeria Ferretti, Emilio Paolo Alessandrino, Giuseppe Rossi, Enrica Morra
High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown effective in the control of relapsed/refractory follicular lymphoma. We evaluate the long-term outcome of patients with relapsed or refractory follicular lymphoma treated with ASCT with in vivo purged progenitors cells. We report the long-term results of a prospective multicenter phase 2 trial on 124 relapsed/refractory follicular lymphoma patients treated with a program of anthracycline-based debulking chemotherapy, immunochemotherapy, mobilization of in vivo purged PBSC followed by ASCT...
March 2015: American Journal of Hematology
https://www.readbyqxmd.com/read/25381127/the-notch-pathway-is-recurrently-mutated-in-diffuse-large-b-cell-lymphoma-associated-with-hepatitis-c-virus-infection
#19
Luca Arcaini, Davide Rossi, Marco Lucioni, Marta Nicola, Alessio Bruscaggin, Valeria Fiaccadori, Roberta Riboni, Antonio Ramponi, Virginia V Ferretti, Stefania Cresta, Gloria Margiotta Casaluci, Maurizio Bonfichi, Manuel Gotti, Michele Merli, Aldo Maffi, Mariarosa Arra, Marzia Varettoni, Sara Rattotti, Lucia Morello, Maria Luisa Guerrera, Roberta Sciarra, Gianluca Gaidano, Mario Cazzola, Marco Paulli
Hepatitis C virus has been found to be associated with B-cell non-Hodgkin lymphomas, mostly marginal zone lymphomas and diffuse large B-cell lymphoma. Deregulation of signaling pathways involved in normal marginal zone development (NOTCH pathway, NF-κB, and BCR signaling) has been demonstrated in splenic marginal zone lymphoma. We studied mutations of NOTCH pathway signaling in 46 patients with hepatitis C virus-positive diffuse large B-cell lymphoma and in 64 patients with diffuse large B-cell lymphoma unrelated to HCV...
February 2015: Haematologica
https://www.readbyqxmd.com/read/25327841/the-use-of-anthracycline-at-first-line-compared-to-alkylating-agents-or-nucleoside-analogs-improves-the-outcome-of-salvage-treatments-after-relapse-in-follicular-lymphoma-the-refoll-study-by-the-fondazione-italiana-linfomi
#20
MULTICENTER STUDY
Giuseppe Rossi, Luigi Marcheselli, Alessandra Dondi, Chiara Bottelli, Alessandra Tucci, Stefano Luminari, Luca Arcaini, Michele Merli, Alessandro Pulsoni, Carola Boccomini, Benedetta Puccini, Moira Micheletti, Giovanni Martinelli, Andrea Rossi, Vittorio Ruggero Zilioli, Valentina Bozzoli, Monica Balzarotti, Silvia Bolis, Maria Giuseppina Cabras, Massimo Federico
Follicular lymphoma (FL) patients experience multiple remissions and relapses and commonly receive multiple treatment lines. A crucial question is whether anthracyclines should be used at first-line or whether they would be better "reserved" for relapse and whether FL outcome can be optimized by definite sequences of treatments. Randomized trials can be hardly designed to address this question. In this retrospective multi-institutional study, time-to-next-treatment after first relapse was analyzed in 510 patients who had received either alkylating agents- or anthracycline- or nucleoside analogs-based chemotherapy with/without rituximab at first-line and different second-line therapies...
January 2015: American Journal of Hematology
keyword
keyword
22729
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"